Fineline Cube

Follow:
14398 Articles
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
Company

Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration

Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
CompanyDeals

Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin

Johnson & Johnson's Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
CompanyDrug

Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
Policy / Regulatory

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
Policy / Regulatory

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024

Alphamab Oncology and CSPC Pharma's KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
CompanyDrug

Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
CompanyDeals

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Shanghai Junshi Biosciences' Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
CompanyDrug

Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
Company

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA
CompanyDrug

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA

Innovec Pharma's IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China's CDE
CompanyDrug

Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE